Skip to main content

Table 1 Patient demographics and baseline characteristics

From: Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs

CharacteristicPlacebo (n = 169)Upadacitinib 15 mg (n = 164)Upadacitinib 30 mg (n = 165)
Age (y), mean ± SD57.6 ± 11.456.3 ± 11.357.3 ± 11.6
Female, n (%)143 (84.6)137 (83.5)138 (83.6)
Race, n (%)
 White143 (84.6)142 (86.6)148 (89.7)
 Black21 (12.4)17 (10.4)10 (6.1)
 Asian5 (3.0)2 (1.2)2 (1.2)
 Other0 (0)3 (1.8)5 (3.0)
BMI (kg/m2), mean ± SD29.7 ± 7.431.2 ± 7.329.7 ± 6.2
Duration of RA (y), mean ± SD14.5 ± 9.212.4 ± 9.412.7 ± 9.7
Failed ≥ 1 anti-TNF, n (%)152 (89.9)146 (89.0)151 (92.1)
Failed ≥ 1 bDMARD due to lack of efficacy, n (%)159 (94.1)146 (89.0)139 (84.8)
  1. bDMARD biologic disease-modifying antirheumatic drug, RA rheumatoid arthritis, SD standard deviation, TNF tumor necrosis factor, y years